000 | 01946 a2200577 4500 | ||
---|---|---|---|
005 | 20250517181207.0 | ||
264 | 0 | _c20180625 | |
008 | 201806s 0 0 eng d | ||
022 | _a1476-511X | ||
024 | 7 |
_a10.1186/s12944-017-0592-5 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aShi, Tianshu | |
245 | 0 | 0 |
_aFenofibrate decreases the bone quality by down regulating Runx2 in high-fat-diet induced Type 2 diabetes mellitus mouse model. _h[electronic resource] |
260 |
_bLipids in health and disease _cOct 2017 |
||
300 |
_a201 p. _bdigital |
||
500 | _aPublication Type: Journal Article | ||
650 | 0 | 4 | _aAnimals |
650 | 0 | 4 |
_aBone Density _xdrug effects |
650 | 0 | 4 |
_aCaspase 3 _xgenetics |
650 | 0 | 4 |
_aCollagen Type I _xgenetics |
650 | 0 | 4 |
_aCore Binding Factor Alpha 1 Subunit _xantagonists & inhibitors |
650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xetiology |
650 | 0 | 4 |
_aDiet, High-Fat _xadverse effects |
650 | 0 | 4 | _aDisease Models, Animal |
650 | 0 | 4 |
_aDyslipidemias _xetiology |
650 | 0 | 4 |
_aFenofibrate _xadverse effects |
650 | 0 | 4 | _aGene Expression Regulation |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aHypolipidemic Agents _xadverse effects |
650 | 0 | 4 | _aMice |
650 | 0 | 4 |
_aOsteoblasts _xdrug effects |
650 | 0 | 4 |
_aOsteocalcin _xgenetics |
650 | 0 | 4 |
_aPorosity _xdrug effects |
650 | 0 | 4 | _aPrimary Cell Culture |
650 | 0 | 4 |
_aProto-Oncogene Proteins c-bcl-2 _xgenetics |
650 | 0 | 4 | _aSignal Transduction |
650 | 0 | 4 | _aX-Ray Microtomography |
700 | 1 | _aLu, Ke | |
700 | 1 | _aShen, Siyu | |
700 | 1 | _aTang, Qiaoli | |
700 | 1 | _aZhang, Kaijia | |
700 | 1 | _aZhu, Xiaobo | |
700 | 1 | _aShi, Yong | |
700 | 1 | _aLiu, Xianglin | |
700 | 1 | _aTeng, Huajian | |
700 | 1 | _aLi, Chaojun | |
700 | 1 | _aXue, Bin | |
700 | 1 | _aJiang, Qing | |
773 | 0 |
_tLipids in health and disease _gvol. 16 _gno. 1 _gp. 201 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1186/s12944-017-0592-5 _zAvailable from publisher's website |
999 |
_c27682396 _d27682396 |